Targeting casein kinase 1 for cancer therapy: current strategies and future perspectives.
RNA interference
cancer therapy
casein kinase 1
clinical strategy
gene targeting
immunotherapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
06
2023
accepted:
07
09
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Casein Kinase 1 (CK1) is a family of serine/threonine protein kinases that play a crucial role in various cellular processes, including cell proliferation, survival, and metabolism. The dysregulation of CK1 expression has been implicated in the development and progression of several types of cancer, making it an attractive target for anticancer therapy. In this review, we provide an overview of the current strategies employed to target CK1 for cancer therapy and discuss the future perspectives in this field. We highlight the different approaches, including small molecule inhibitors, RNA interference, genome editing, and immunotherapies, which hold immense potential for targeted modulation of CK1 activity in cancer cells. Furthermore, we discuss the challenges associated with targeting CK1 and propose potential strategies to overcome these hurdles. Overall, targeting CK1 holds great promise as a therapeutic strategy for cancer treatment, and further research in this area is warranted.
Identifiants
pubmed: 38023245
doi: 10.3389/fonc.2023.1244775
pmc: PMC10666751
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1244775Informations de copyright
Copyright © 2023 Long and Lee.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Immunol. 2019 Sep 26;10:2293
pubmed: 31616443
iScience. 2022 Jun 16;25(7):104624
pubmed: 35800758
Arch Immunol Ther Exp (Warsz). 2021 Sep 18;69(1):26
pubmed: 34536148
EMBO Rep. 2018 Apr;19(4):
pubmed: 29514862
PLoS One. 2021 Apr 16;16(4):e0246264
pubmed: 33861751
Nat Commun. 2021 Sep 10;12(1):5386
pubmed: 34508104
Lancet. 2017 Jun 17;389(10087):2430-2442
pubmed: 27939063
Cancer Metastasis Rev. 2018 Mar;37(1):107-124
pubmed: 29243000
Cancer Res. 2015 Nov 15;75(22):4937-48
pubmed: 26490646
Biochim Biophys Acta. 2015 Jul;1849(7):830-5
pubmed: 25252159
Nucleic Acids Res. 2017 Oct 13;45(18):10800-10810
pubmed: 28985357
Front Oncol. 2019 Nov 12;9:1211
pubmed: 31799185
Curr Top Dev Biol. 2017;123:303-329
pubmed: 28236970
Cancer Cell. 2009 Nov 6;16(5):401-12
pubmed: 19878872
Int J Mol Sci. 2020 Aug 18;21(16):
pubmed: 32824859
Blood. 2018 Mar 15;131(11):1206-1218
pubmed: 29317454
Adv Pharm Bull. 2014 Dec;4(4):313-21
pubmed: 25436185
J Biol Chem. 2000 Jun 30;275(26):20052-60
pubmed: 10749871
Front Immunol. 2016 Oct 27;7:460
pubmed: 27833613
Int J Mol Sci. 2021 Mar 05;22(5):
pubmed: 33807717
Oncologist. 2015 Aug;20(8):847-8
pubmed: 26173838
Int J Cancer. 2015 Jun 15;136(12):2799-810
pubmed: 25404202
FEBS J. 2023 Jun;290(11):2845-2864
pubmed: 35313089
Cell Signal. 2023 Aug;108:110733
pubmed: 37257767
Expert Opin Investig Drugs. 2011 Feb;20(2):153-208
pubmed: 21235428
Exp Eye Res. 2022 May;218:109004
pubmed: 35219693
Front Oncol. 2014 May 19;4:96
pubmed: 24904820
PLoS Genet. 2015 May 20;11(5):e1005225
pubmed: 25993311
Cancers (Basel). 2023 Apr 15;15(8):
pubmed: 37190239
Biochem Soc Trans. 2018 Jun 19;46(3):761-771
pubmed: 29871876
J Cell Physiol. 2019 Feb;234(2):1313-1325
pubmed: 30191996
Front Immunol. 2016 Sep 22;7:378
pubmed: 27713747
Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E10871-E10880
pubmed: 29208719
Sci Transl Med. 2023 May 24;15(697):eadf2281
pubmed: 37224228
Lancet Haematol. 2019 Jan;6(1):e38-e47
pubmed: 30558987
Front Immunol. 2018 Apr 13;9:745
pubmed: 29706964
Int J Mol Sci. 2020 Apr 25;21(9):
pubmed: 32344896
Cancer Res. 2014 Jan 1;74(1):201-11
pubmed: 24247720
Elife. 2019 Sep 30;8:
pubmed: 31567070
Nat Commun. 2017 Dec 13;8(1):2095
pubmed: 29235474
Blood. 2022 Oct 20;140(16):1753-1763
pubmed: 35512188
Int J Mol Sci. 2020 Nov 27;21(23):
pubmed: 33261128
Cell Death Dis. 2019 Dec 4;10(12):923
pubmed: 31801942
PLoS One. 2017 Jan 26;12(1):e0170903
pubmed: 28125685
Nat Immunol. 2016 Apr;17(4):397-405
pubmed: 26928339
Mol Cell Biol. 2009 Dec;29(24):6401-12
pubmed: 19805514
Lancet Haematol. 2019 Feb;6(2):e100-e109
pubmed: 30709431
Sci Signal. 2013 Jan 22;6(259):ra5
pubmed: 23354688
Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1381-6
pubmed: 26787912
Mol Cancer. 2014 Oct 11;13:231
pubmed: 25306547
Sci Transl Med. 2015 Dec 16;7(318):318ra202
pubmed: 26676609
Mol Cell Biol. 2005 Aug;25(15):6509-20
pubmed: 16024788
EMBO Mol Med. 2012 Sep;4(9):952-63
pubmed: 22707389
Mol Pain. 2014 Mar 10;10:17
pubmed: 24612480
Oncotarget. 2018 Jul 20;9(56):30821-30836
pubmed: 30112110
Curr Med Chem. 2021;28(8):1585-1604
pubmed: 32660395
J Biol Rhythms. 2019 Apr;34(2):144-153
pubmed: 30898060
Expert Opin Ther Targets. 2014 Aug;18(8):835-9
pubmed: 24917359